April 2021, Drugs Monitor, Page 5

(19 Mar 2021) Colchicine- 1 mg for 1-3 days followed by 0.5 mg/day for 14 days effective as a proactive anti-inflammatory

April 7, 2021

Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study https://doi.org/10.18087/cardio.2021.2.n1560 In the control group, the CRP levels decreased moderately and statistically insignificantly and achieved 22.8 mg/dL by… Continue reading "(19 Mar 2021) Colchicine- 1 mg for 1-3 days followed by 0.5 mg/day for 14 days effective as a proactive anti-inflammatory"

(19 Mar 2021) Favipiravir- did not shorten time to clinical recovery and length of hospital stay

April 7, 2021

Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia https://doi.org/10.1016/j.intimp.2021.107522 IRCT20200318046812N1- 380 patients were randomly allocated into Favipiravir (193) and Lopinavir/Ritonavir (187) groups in 13 centers. The number of deaths, intubations, and ICU admissions were not significantly different… Continue reading "(19 Mar 2021) Favipiravir- did not shorten time to clinical recovery and length of hospital stay"

(18 Mar 2021) Favipiravir- was more effective than LPV/RTV in reducing mortality

April 7, 2021

The Comparison of Lopinavir/Ritonavir Combination and Favipiravir In COVID-19 Treatment https://doi.org/10.3906/sag-2012-189 Of the 204 patients with COVID-19 pneumonia, 59 (28.9%), 131 (64.2%), and 14 were administered LPV/RTV, favipiravir, and favipiravir with LPV/RTV, respectively. No difference was found in age, sex,… Continue reading "(18 Mar 2021) Favipiravir- was more effective than LPV/RTV in reducing mortality"

(17 Mar 2021) Ivermectin- reduction in SARS-CoV-2 viral load within 7 days

April 7, 2021

Use of ivermectin in the treatment of Covid-19: A pilot trial https://doi.org/10.1016/j.toxrep.2021.03.003 NCT04431466- A total of 32 patients were enrolled and randomized to treatment. SOC treatment together with ivermectin did not result in any serious adverse events. All patients exhibited… Continue reading "(17 Mar 2021) Ivermectin- reduction in SARS-CoV-2 viral load within 7 days"

(16 Mar 2021) Corticosteroids- shorter courses of corticosteroids are associated with an increased risk of being readmitted

April 7, 2021

Short durations of corticosteroids for hospitalised COVID-19 patients are associated with a high readmission rate https://doi.org/10.1016/j.jinf.2021.03.002 196 patients were admitted from the community with a diagnosis of COVID-19 and discharged alive in December 2020. Corticosteroids were prescribed in hospital for… Continue reading "(16 Mar 2021) Corticosteroids- shorter courses of corticosteroids are associated with an increased risk of being readmitted"

(16 Mar 2021) Enoxaparin- associated with lower rates of mortality than unfractionated Heparin

April 7, 2021

Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients https://doi.org/10.1016/j.eclinm.2021.100774 We find that COVID-19 patients administered unfractionated Heparin but not Enoxaparin have higher rates of 28-day mortality (risk ratio: 4.3; 95% Confidence Interval [C.I.].:… Continue reading "(16 Mar 2021) Enoxaparin- associated with lower rates of mortality than unfractionated Heparin"

(14 Mar 2021) PEG IFN-alpha2b- 80% subjects had a negative RT-PCR result on day 7

April 7, 2021

Efficacy and Safety of Pegylated Interferon alfa-2b in Moderate COVID-19: A phase II, randomized, controlled, open-label study https://doi.org/10.1016/j.ijid.2021.03.015 CTRI/2020/06/026087- In this phase 2, randomized, open-label study, adult subjects aged >18 years with RT-PCR confirmed COVID-19 with moderate symptoms were randomized… Continue reading "(14 Mar 2021) PEG IFN-alpha2b- 80% subjects had a negative RT-PCR result on day 7"

(10 Mar 2021) Tocilizumab- improved hypoxia without unacceptable side effect profile

April 7, 2021

Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial https://doi.org/10.1007/s11684-020-0824-3 ChiCTR2000029765- The patients were randomly assigned in a 1:1 ratio to receive either tocilizumab in addition to standard care or standard care alone. The cure… Continue reading "(10 Mar 2021) Tocilizumab- improved hypoxia without unacceptable side effect profile"

(10 Mar 2021) Remdesivir- no positive effect on clinical outcomes

April 7, 2021

Efficacy of remdesivir in Japanese patients hospitalised with COVID-19: A large observational study using the COVID-19 Registry Japan https://www.medrxiv.org/content/10.1101/2021.03.09.21253183v1 In total, 1907 of 15,225 patients met our inclusion criteria. After PS matching, 74 patients were assigned to the remdesivir case… Continue reading "(10 Mar 2021) Remdesivir- no positive effect on clinical outcomes"

(09 Mar 2021) Methylprednisolone- Survival at 28 days was 98.6%

April 7, 2021

Single-Arm, Open-Label Phase 2 Trial of Preemptive Methylprednisolone to Avert Progression to Respiratory Failure in High-Risk Patients with COVID-19 https://www.medrxiv.org/content/10.1101/2021.03.08.21253117v1 NCT04355247 -Eligible patients were those 21 years or older with a diagnosis of Covid-19 and oxygen saturation ≥91%. For patients to… Continue reading "(09 Mar 2021) Methylprednisolone- Survival at 28 days was 98.6%"

Month: April 2021